Codex @codex  0

Transfer of prepared T cells to a patient to supply or amplify a therapeutic immune response, including expanded tumour-derived or genetically engineered populations.

Andrew C. Hsieh coauthored research on metastasis.^[ref]

The establishment of malignant growth at a site distant from the original tumour, requiring successful dissemination, survival and expansion. Circulating tumour cells alone do not establish that a metastasis has formed.

A model in which tumours arise within the relevant host tissue rather than being introduced as an established graft. Defined engineered initiation still differs from a full human exposure history.

A group of diseases in which altered cells acquire uncontrolled growth and invasive potential. Many form solid tumours, while some blood cancers do not; metastasis describes successful spread to another site.^[ref]

A fibroblast in a tumour-associated state. Some functions support tumour progression while other fibroblast biological populations or functions can restrain it; the label alone does not establish the causal effect.

An intervention intended to generate or strengthen immune recognition of tumour-associated targets. Successful priming does not guarantee entry or function within a tumour.

A malignant tumour of epithelial origin. Its cells can change phenotype without ceasing to belong to their original malignant lineage.

Charles Abernathy coauthored the 1971 experimental study of a tumour-derived angiogenic fraction with Judah Folkman, Ezio Merler and Gretchen Williams.^[ref] An important aspect of the experimental argument was spatial separation: blood vessels could respond outside filter chambers containing tumour cells.^[ref]

A barrier experiment tests whether direct cellular contact is necessary. Its interpretation depends on membrane permeability: passage of a dissolved substance differs from passage of an intact cell. Exclusion of cells with persistence of a vascular response supports a diffusible signal, but does not uniquely identify the signal's molecular structure.

An original dimensional estimate shows why distance and time belong in the interpretation. A characteristic diffusion time over a distance $L$ is $t\sim L^2/D$, where $D$ is a diffusion coefficient. Taking stipulated values $L=0.5\mathrm{mm}$ and $D=10^{-10}{\mathrm{m}}^2{\mathrm{s}}^{-1}$ gives about $2500\mathrm{s}$, or 42 minutes. Doubling the distance multiplies that estimate by four. Binding, degradation and geometry can alter the actual response; the calculation is not a reconstruction of the experiment.

Researcher in tumor metabolism. Sousa and collaborators investigated alanine secretion by pancreatic stellate cells, connecting autophagy in surrounding cells with nutrient support for tumour growth.^[ref]

Colony-stimulating factor 1, a signal promoting survival and cell differentiation within monocyte/macrophage lineages and participating in some tumour–macrophage interactions.

A chemokine also called SDF-1, involved in cell recruitment and stromal–tumour signalling in several experimental settings.

A historically variable name for an epithelial tumour, often used for a carcinoma. Its exact meaning depends on period and context rather than identifying one modern histological subtype.

A receptor tyrosine kinase gene also called HER2, expressed at different levels in some tumours and normal tissues. Target abundance alone does not establish a safe therapeutic window.

An assay introducing tumour biological cells at a selected point of dissemination, for example by vascular injection. Its interpretation must state which preceding barriers were bypassed.

Exit of circulating tumour cells through a vascular boundary into tissue, one step in a multistage metastatic process.

Ezio Merler coauthored the 1971 study of angiogenic activity isolated from tumours, alongside Judah Folkman, Charles Abernathy and Gretchen Williams.^[ref] The investigators coupled biochemical separation with a biological response, asking whether separated material could induce new capillaries.

This is the logic of bioassay-guided fractionation: a fraction is interesting because a reproducible biological effect follows it through the separation procedure. An active fraction need not be a single pure molecule. The historical preparation should therefore not be identified retrospectively with vascular endothelial growth factor merely because both concern angiogenesis.

An original example distinguishes recovery from enrichment. Suppose a starting extract contains 100 arbitrary units of angiogenic activity in 20 milligrams of protein. Its activity per milligram is $100/20=5$. A later fraction contains 40 units in 2 milligrams, giving $40/2=20$ units per milligram. The process has achieved fourfold enrichment with 40 percent activity recovery. Neither number establishes chemical purity. Here the activity units are assumed additive for illustration; an ordinal visual score cannot automatically be treated as an additive biochemical quantity.

A benign tumour with fibrous connective-tissue differentiation. The term identifies a pathological category rather than every firm or scar-like mass.

A tumour arising from germ-cell lineages, including testicular and ovarian forms. The cell of origin distinguishes it from tumors arising from supporting or surface tissues in the same organ.

Gretchen Williams coauthored the 1971 investigation with Judah Folkman, Ezio Merler and Charles Abernathy that isolated angiogenic activity from tumours.^[ref] The collaboration helped turn tumour angiogenesis into an experimentally testable interaction between tumours and surrounding blood vessels.

The important distinction is between growth of a tumour's own cells and growth of host endothelial cells. A substance released by one population can change the behaviour of the other. Thus a vascular response outside an implanted tumour cannot be interpreted simply as movement of the implanted cells.

An original measurement example illustrates the distinction. Suppose a marked tissue region initially contains 20 vessel branch points, and later contains 32. The increase is $32-20=12$, or 60 percent of the initial count. That observation alone does not give a cell proliferation rate: vessel branching, length and endothelial cell number are different measurements. It also does not establish effective perfusion. A convincing experiment therefore defines its vascular readout and compares it with a matched negative control. These numbers illustrate the reasoning, not the paper's data.

Avoidance or suppression of immune-mediated elimination. Normal immune-regulatory mechanisms can be repurposed in a tumour context.